Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
UNITED STATES GOVERNMENT maintains a company patent portfolio focused on the Biotechnology & Pharmaceuticals technology area. The data shows 1 pending office action currently active. This action is assigned to 1 distinct examiner and 1 distinct art unit. This distribution signifies a concentrated effort in a single technical domain for the government's current filings.
The busiest examiner for this portfolio is KIM, TAEYOON. This examiner is responsible for 1 pending office action. Because the total count of pending actions is 1, KIM, TAEYOON manages the entirety of the government's active prosecution workload. No other examiners are currently reviewing pending matters for this entity.
The involvement of 1 distinct art unit indicates that the pending technology is classified within a specific group. Practitioners can focus their prosecution strategy on the standards of that art unit and the specific tendencies of KIM, TAEYOON. This centralized structure for the 1 pending office action allows for a direct relationship with the assigned examiner in the Biotechnology & Pharmaceuticals sector.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KIM, TAEYOON | 1 | 51.4% | +52.2% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18288358 | LENTIVIRAL VECTORS USEFUL FOR THE TREATMENT OF DISEASE | KIM, TAEYOON | — |
| Art Unit | Apps |
|---|---|
| 1631 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18288358 | LENTIVIRAL VECTORS USEFUL FOR THE TREATMENT OF DISEASE | KIM, TAEYOON | 1631 | §103 | Non-Final OA | — | Pending | Oct 25, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialUNITED STATES GOVERNMENT has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Taeyoon Kim has the most, with 1 of UNITED STATES GOVERNMENT's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.